These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
566 related articles for article (PubMed ID: 29172076)
21. Induction therapy of AML with ara-C plus daunorubicin versus ara-C plus gemtuzumab ozogamicin: a randomized phase II trial in elderly patients. Brunnberg U; Mohr M; Noppeney R; Dürk HA; Sauerland MC; Müller-Tidow C; Krug U; Koschmieder S; Kessler T; Mesters RM; Schulz C; Kosch M; Büchner T; Ehninger G; Dührsen U; Serve H; Berdel WE Ann Oncol; 2012 Apr; 23(4):990-6. PubMed ID: 21810729 [TBL] [Abstract][Full Text] [Related]
22. Antibody-based therapy of acute myeloid leukemia with gemtuzumab ozogamicin. Cowan AJ; Laszlo GS; Estey EH; Walter RB Front Biosci (Landmark Ed); 2013 Jun; 18(4):1311-34. PubMed ID: 23747885 [TBL] [Abstract][Full Text] [Related]
23. FDA Approval: Gemtuzumab Ozogamicin for the Treatment of Adults with Newly Diagnosed CD33-Positive Acute Myeloid Leukemia. Jen EY; Ko CW; Lee JE; Del Valle PL; Aydanian A; Jewell C; Norsworthy KJ; Przepiorka D; Nie L; Liu J; Sheth CM; Shapiro M; Farrell AT; Pazdur R Clin Cancer Res; 2018 Jul; 24(14):3242-3246. PubMed ID: 29476018 [TBL] [Abstract][Full Text] [Related]
24. Clinical Benefits and Safety of Gemtuzumab Ozogamicin in Treating Acute Myeloid Leukemia in Various Subgroups: An Updated Systematic Review, Meta-Analysis, and Network Meta-Analysis. Xu Q; He S; Yu L Front Immunol; 2021; 12():683595. PubMed ID: 34484181 [TBL] [Abstract][Full Text] [Related]
26. Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells. Lu C; Hassan HT Leuk Res; 2006 Mar; 30(3):296-302. PubMed ID: 16112192 [TBL] [Abstract][Full Text] [Related]
27. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. Burnett AK; Hills RK; Milligan D; Kjeldsen L; Kell J; Russell NH; Yin JA; Hunter A; Goldstone AH; Wheatley K J Clin Oncol; 2011 Feb; 29(4):369-77. PubMed ID: 21172891 [TBL] [Abstract][Full Text] [Related]
28. Sequence of administration and methylation of SOCS3 may govern response to gemtuzumab ozogamicin in combination with conventional chemotherapy in patients with refractory or relapsed acute myelogenous leukemia (AML). Middeldorf I; Galm O; Osieka R; Jost E; Herman JG; Wilop S Am J Hematol; 2010 Jul; 85(7):477-81. PubMed ID: 20575043 [TBL] [Abstract][Full Text] [Related]
29. A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Petersdorf SH; Kopecky KJ; Slovak M; Willman C; Nevill T; Brandwein J; Larson RA; Erba HP; Stiff PJ; Stuart RK; Walter RB; Tallman MS; Stenke L; Appelbaum FR Blood; 2013 Jun; 121(24):4854-60. PubMed ID: 23591789 [TBL] [Abstract][Full Text] [Related]
30. Rationale and design of the 2 by 2 factorial design GnG-trial: a randomized phase-III study to compare two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and to compare double-blinded intensive postremission therapy with or without glasdegib in older patients with newly diagnosed AML. Jaramillo S; Krisam J; Le Cornet L; Kratzmann M; Baumann L; Sauer T; Crysandt M; Rank A; Behringer D; Teichmann L; Görner M; Trappe RU; Röllig C; Krause S; Hanoun M; Hopfer O; Held G; Buske S; Fransecky L; Kayser S; Schliemann C; Schaefer-Eckart K; Al-Fareh Y; Schubert J; Geer T; Kaufmann M; Brecht A; Niemann D; Kieser M; Bornhäuser M; Platzbecker U; Serve H; Baldus CD; Müller-Tidow C; Schlenk RF Trials; 2021 Nov; 22(1):765. PubMed ID: 34732236 [TBL] [Abstract][Full Text] [Related]
31. Gemtuzumab ozogamicin for the treatment of acute myeloid leukemia in adults. Goldenson BH; Goodman AM; Ball ED Expert Opin Biol Ther; 2021 Jul; 21(7):849-862. PubMed ID: 32990476 [TBL] [Abstract][Full Text] [Related]
32. The addition of gemtuzumab ozogamicin to chemotherapy in adult patients with acute myeloid leukemia. Kell J Expert Rev Anticancer Ther; 2016; 16(4):377-82. PubMed ID: 26942450 [TBL] [Abstract][Full Text] [Related]
33. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. Hills RK; Castaigne S; Appelbaum FR; Delaunay J; Petersdorf S; Othus M; Estey EH; Dombret H; Chevret S; Ifrah N; Cahn JY; Récher C; Chilton L; Moorman AV; Burnett AK Lancet Oncol; 2014 Aug; 15(9):986-96. PubMed ID: 25008258 [TBL] [Abstract][Full Text] [Related]
34. Gemtuzumab ozogamicin plus midostaurin in combination with standard '7 + 3' induction therapy in newly diagnosed AML: Results from the SAL-MODULE phase I study. Röllig C; Schliemann C; Ruhnke L; Fransecky L; Heydrich BN; Hanoun M; Noppeney R; Schäfer-Eckart K; Wendelin K; Mikesch JH; Middeke JM; Reimann M; Fiebig F; Zukunft S; Wermke M; Serve H; Platzbecker U; Müller-Tidow C; Baldus CD; Bornhäuser M Br J Haematol; 2024 Jun; 204(6):2254-2258. PubMed ID: 38593353 [TBL] [Abstract][Full Text] [Related]
35. Gemtuzumab Ozogamicin Reduces Relapse Risk in FLT3/ITD Acute Myeloid Leukemia: A Report from the Children's Oncology Group. Tarlock K; Alonzo TA; Gerbing RB; Raimondi SC; Hirsch BA; Sung L; Pollard JA; Aplenc R; Loken MR; Gamis AS; Meshinchi S Clin Cancer Res; 2016 Apr; 22(8):1951-7. PubMed ID: 26644412 [TBL] [Abstract][Full Text] [Related]
36. Fractionated gemtuzumab ozogamicin and standard dose cytarabine produced prolonged second remissions in patients over the age of 55 years with acute myeloid leukemia in late first relapse. Pilorge S; Rigaudeau S; Rabian F; Sarkozy C; Taksin AL; Farhat H; Merabet F; Ghez S; Raggueneau V; Terré C; Garcia I; Renneville A; Preudhomme C; Castaigne S; Rousselot P Am J Hematol; 2014 Apr; 89(4):399-403. PubMed ID: 24375467 [TBL] [Abstract][Full Text] [Related]